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ABSTRACT
Objective: Angiotensin receptor blockers (ARBs) are effective hypertensive drugs. Reduction in risk of lung cancer with ARBs was proven in clinical 
studies. Telmisartan and irbesartan are the second-generation ARBs. This study screens the anticancer activity of these two drugs in a dose-dependent 
manner using A549 cell line.
Methods: Different concentrations of irbesartan and telmisartan were treated on A549 cells and the anticancer activity was evaluated through 
methylthiazolyldiphenyl-tetrazolium [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] cytotoxicity assay. The dot plot of the 
cytotoxicity results was used to extrapolate the half maximal inhibitory concentration (IC50) values. Microscopic changes in the cells post-treatment 
with these drugs were also recorded at ideal concentrations.
Results: A reduction in cell viability was noted in A549 cells with increasing concentration of the drug. The IC50 values for irbesartan and telmisartan 
were 31.1 µg and 15.6 µg, respectively. Microscopic observation of the cells shows more rounded and deformed dead cells on telmisartan- and 
irbesartan-treated cells when compared with the untreated control.
Conclusion: The results confirm the anticancer activity of both the drugs with telmisartan being more efficient. The anticancer activity could probably 
be due to the role of irbesartan and telmisartan in inhibiting mitogen-activated protein kinase cell survival pathway and local angiogenesis.
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INTRODUCTION
Angiotensin receptor blockers (ARBs) are antagonists to angiotensin II 
as it binds to angiotensin II receptor type I and blocks vasoconstriction, 
retention of sodium and water, cell proliferation, aldosterone release, 
and sympathetic nerve activation [1,2]. ARBs are safe approved drugs 
since the 1990s widely used to treat atherosclerosis, cardiovascular 
diseases, and blood pressure and have been included in commonly 
prescribed drug for the treatment of hypertension [3,4]. Losartan, 
candesartan, telmisartan, valsartan, and irbesartan are few of the 
approved ARBs. Telmisartan and irbesartan are metabosartans 
classified under the second-generation ARBs with a protective effect on 
diabetic nephropathy [5]. Adding on telmisartan has also substantially 
proven neuroprotective effects by possessing anti-inflammatory 
properties, in stroke patients [6].
There were conflicting reports on the association of ARBs with cancer. 
Candesartan in heart failure assessment of reduction in mortality and 
morbidity study showed that there were more fatal cancers in patients 
administered candesartan than placebo [7]. Meta-analysis using 
randomized controlled trials performed by Sipahi et al. [8] reported 
association of unassuming increased risk of new cancer diagnosis 
and ARBs. Later, a cohort study observed an apparently protective 
association between the use of ARBs and lung cancer [9]. Another meta-
analysis study reported decreased lung cancer risk with ARBs [10].
Lung cancer prevalence among newly diagnosed cases of cancer and 
cancer deaths constitutes 13% and 19%, respectively, worldwide [11]; 
6.9% and 9.3%, respectively, in India [12]. Its prevalence and mortality 
are due to lack of early detection of the illness, which risks the patient’s 
life [13]. Due to the association of ARBs to lung cancer, the present 
study aims to demonstrate the anticancer activity of the two drugs 
telmisartan and irbesartan using methylthiazolyldiphenyl-tetrazolium 
bromide (MTT) assay on cell lines. A lung cancer cell line human lung 
alveolar epithelial cells derived carcinoma cell line A549 was used 
for analysis. Telmisartan and irbesartan were added to A549 cells at 
different concentration to determine the effect of these drugs on cancer 
cell viability in a dose-dependent manner.
METHODS
Cell line and culture
A549 cell line was provided by the National Centre for Cell Sciences, 
Pune. The cells were cultured and maintained in cell culture media, 
minimal essential medium (MEM) composed with antibiotics such as 
streptomycin (100 μg/ml) and penicillin (100 U/ml), 10% fetal bovine 
serum (FBS) in a suitable temperature (37°C), and atmosphere (5% 
CO2).
Reagents
FBS and MEM were purchased from Cistron Laboratories (Chennai, 
India) and Hi-Media Laboratories (Mumbai, India), respectively. 
Dimethyl sulfoxide (DMSO), MTT, and trypsin were obtained from Sisco 
Research Laboratory Chemicals (Mumbai, India). Other reagents and 
chemicals were provided by Sigma-Aldrich (Mumbai).
MTT Cytotoxicity assay
The MTT assay for determining the tumor cell cytotoxicity of the two 
drugs was performed according to the method of Mosmann [14]. 
Briefly, cells (1×105/well) were plated in 24-well plates and incubated 
at 37°C with 5% CO2 atmosphere. On reaching confluence, the cells 
were washed in phosphate-buffered saline (PBS) and the medium was 
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changed. Increasing concentrations of both the drugs obtained through 
serial dilution were added to the different wells and were marked, 
respectively. One of the wells was treated only with the diluent which 
served as the control. Cell control and drug control were included in 
each assay. The culture plates were kept under incubation for 24 h at 
37°C with 5% CO2 atmosphere. The medium was separated from wells 
after incubation, then PBS with pH 7.4 was used for washing the cells. 
100 µl/well of 0.5% MTT (5 mg/ml) was added to each well and the 
cell plate was kept under incubation for 4 h. After incubation, 1 ml of 
DMSO was added in all the wells. This helps in dissolving the insoluble 
crystalline formazan product for effective absorbance measurement. 
UV spectrophotometry was used to measure the absorbance at 570 nm; 
taking DMSO as blank, and the results were tabulated using the formula 
as follows:
Absorbance of Treated 
A549 cells % Cell viability= *100
Absorbance of Control 
A549 cells
RESULTS
The absorbance results of MTT assay and the resultant cell viability 
percentage are tabulated in Table 1 for telmisartan and Table 2 for 
irbesartan.
Half maximal inhibitory concentration (IC50) level of irbesartan was 
31.2 µg and that of telmisartan was 15.6 µg, respectively. This suggests 
that telmisartan is more cytotoxic than irbesartan. MTT cytotoxicity 
assay reveals an increase in cell death corresponding to an increase in 
the concentration of both irbesartan and telmisartan.
Effect of the drug telmisartan and irbesartan on the A549 cells was 
observed in a phase contrast microscope, and the results are presented 
in Fig. 1 (telmisartan) and Fig. 2 (irbesartan).
DISCUSSION
Our study proves the anticancer activity of these antihypertensive 
drugs. Both the drugs were able to establish a good cytotoxicity at 
lower concentrations indicating that more studies on this field will 
potentially establish an effective anticancer drug for treating lung 
cancers. The dot plots of the MTT assay reveal a steep decrease in 
the cell viability with increasing concentrations of both telmisartan 
and irbesartan. On extrapolating the IC50 values from the graph, it is 
shown that telmisartan is more effective than irbesartan. Almost half 
the concentration of telmisartan (15.6 µg/ml) was able to establish the 
IC50 when compared to irbesartan (31.2 µg/ml). This suggests that 
telmisartan will be a better drug of choice for future study. Microscopic 
observation showed a clear decrease in the live cells when compared to 
control at the IC50 concentration. Dead cells were seen with distorted 
and rounded morphology. There were few live elongated cells with 
normal morphology in Panel D and Panel C while there were no live 
cells at all in Panel B in comparison with Panel A. This was true for 
both telmisartan and irbesartan. This clearly shows that the drugs can 
induce cell death in these lung cancer cell models and thereby can stand 
as an effective anticancer drug.
Previous studies on telmisartan and irbesartan have demonstrated 
their ability to block cell proliferation in a dose-dependent manner. 
This property of these drugs was found to be due to its ability to block 
extracellular signal-regulated kinase (ERK) activation in aortic vascular 
smooth muscle [15]. ERK is one of the major mitogen-activated protein 
kinase (MAPK) signals that the cancer cells use for cell proliferation 
[16]. This could probably be the reason for the anticancer property 
noted in our study. More study in this line is required to demonstrate 
the involvement of MAPK signals in telmisartan- and irbesartan-
induced anticancer activity. Further, the effect of irbesartan in blocking 
hypoxia-induced angiogenesis has also been reported [17].
The main reasons for cancer cell survival and proliferation are 
increased local angiogenesis [18,19], growth suppressor evasion, 
cell death inhibition, and increased activation of MAPK survival 
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thus promoting the cancerous property [20]. This uncontrolled cell 
growth, activation of invasion and metastasis, and host immunity 
avoidance are few of the other properties that retain the cancerous 
nature of these cells [21]. Nowadays, surgery, chemotherapy, radiation, 
hormones, and immunotherapy are the main approaches for the cancer 
treatment. Several problems are associated with the existing treatment 
methods which include limited efficacy, severe toxicity, and multidrug 
resistance [22]. This work is the first of its kind in demonstrating the 
anticancer activity of telmisartan and irbesartan in a dose-dependent 
manner. These antihypertensive drugs have been found to have 
inhibitory roles on the two key processes of cancer, i.e., angiogenesis 
and MAPK pathway and thus can stand as an effective anticancer drug. 
This will pave the way for generating novel anticancer drugs with the 
drugs existing in the market which are relatively less toxic and more 
effective. The in vitro screening of drugs for anticancer activity is 
technically simple, quick, cost-effective, and reproducible and provides 
information about the targets of anticancer action. However, this method 
has its own limitations as it is error prone and only few molecules reach 
the human clinical trials. Hence, we need to further extend the study in 
various in vitro methods and in vivo experimentation in animal models 
of cancer [23].
CONCLUSION
The study drugs ARBs telmisartan and irbesartan show anticancer 
activity on the A549 lung carcinoma cell lines. These study results 
establish a good anticancer activity at lower concentrations of these 
drugs indicating that more studies on this field are further needed to 
establish their molecular mechanism of action and to substitute them 
as effective adjuvant anticancer drugs for lung carcinoma and other 
cancers which might be safe, tolerable, and effective.
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